Table 1:

Descriptive Characteristics of RA Patients Tested with the MBDA, Stratified by Level of Disease Activity (N=60,596)

	MBDA Score Category
	Low (<30)	Moderate (30–44)	High (>44)
Demographics  Age, mean+/-SD, years  Female, %  Low income, %  Disability (as reason for Medicare entitlement), %	66.4 +− 11.3 74.0 30.9 40.4	69.4 +− 10.2 79.1 26.5 35.5	69.7 +− 10.5 80.5 27.8 38.8
Comorbidities, %  Fibromyalgia  Diabetes  Chronic Pulmonary Disease  Obesity (as a diagnosis)  Charlson comorbidity index   0   1   2   3+	18.4 15.6 14.2 3.6 7.6 51.1 22.6 18.7	17.8 19.6 17.8 5.2 6.1 44.5 23.6 25.8	16.5 24.8 23.8 6.8 4.7 37.7 24.6 33.0
Medication  TNFi biologic  nonTNFi biologic or JAKi  Methotrexate  HCQ, LEF, SSZ  Oral glucocorticoids	37.4 13.2 49.1 36.5 31.3	30.1 16.7 51.0 36.4 37.9	23.4 21.5 48.2 36.0 50.7
Health Services Utilization
Number of ambulatory visits  Any hospitalization, %	8.0 (5.5) 6.2	8.5 (5.7) 8.5	9.4 (6.3) 14.1

Data shown as mean +− standard deviation or % All differences are significant at p < 0.0001 except for the comparison of HCQ/LEF/SSZ which was not significant

TNFi = tumor necrosis factor inhibitor, JAKi = janus kinase inhibitor; HCQ = hydroxychloroquine; SSZ = sulfasalazine; LEF = leflunomidie